Therapeutic Solutions International Discovers and Files Patent on Novel Cellular Therapy Combination for Augmentation of Lung Repair in COVID-19 Model

Rhea-AI Summary

Therapeutic Solutions International (OTC Markets: TSOI) announced promising data and a new patent for a cellular therapy aimed at reducing lung injury and promoting lung regeneration. The research shows that combining T regulatory cells from umbilical cord blood with JadiCells effectively suppresses lung damage in experimental models. The findings suggest a molecular mechanism involving the GITR pathway that enhances therapy efficacy. The company is preparing to launch an FDA Phase III trial for COVID-19 patients while exploring additional molecular switches to improve stem cell activity.

Positive

• Discovery of a patent for a novel cellular therapy that combines T regulatory cells and JadiCells.
• Effective in suppressing lung damage in COVID-19 models, indicating potential for significant therapeutic impact.
• Preparation for an FDA Phase III trial, suggesting readiness to advance clinical research.

Negative

• None.

ELK CITY, Idaho, Sept. 22, 2021 /PRNewswire/ -- Therapeutic Solutions International, Inc., (OTC Markets: TSOI), announced today novel data and filing of a patent demonstrating synergistic suppression of lung injury and acceleration of lung regeneration by combining T regulatory cells and JadiCells.

In a series of experiments synergistic suppression of lung damage was observed in the endotoxin and Poly (IC) models when umbilical cord blood T regulatory cells were co-administered with JadiCells.  Furthermore, blockade of GITR, a member of the TNF receptor superfamily, resulted in suppression of synergy, suggesting a molecular mechanism of this interaction.

"I believe science does not stop and cannot be stopped.  Therefore, as a Company, we are always seeking new ways of enhancing efficacy of our therapies, as well as elucidating molecular mechanisms causing our therapies to work," said Dr. James Veltmeyer, Chief Medical Officer of the Company. "The current discovery provides for novel means of suppressing lung damage, as well as preventing long term-scarring which is a major issue in certain COVID-19 patients."

Lung damage after COVID-19 is believed to be caused by deposition of scar tissue in the functional areas of the lung, which has been quantified to cause dysfunctional breathing for as long as 9 months after infection¹.   JadiCells, as well as QuadraMune®, a commercially available nutraceutical developed by the Company have been shown to reduce lung scarring in other experiments.

"As the COVID-19 pandemic continues its merciless progression, it is becoming more and more important to create second and third generation approaches," said Famela Ramos, Vice President of Business Development. "Today's findings open the door not only towards new approaches but also towards alternative means of manipulating JadiCells using the newly discovered importance of the GITR pathway."

"We are currently continuing experiments to try to identify other molecular switches which can be used to not only enhance JadiCell activity but also activity of numerous other types of stem cells," said Timothy Dixon, President and CEO of the Company and co-inventor of patent. "As we are preparing to initiate the recently cleared FDA Phase III trial on COVID-19 patients, we wish to know as many details as possible about our cells in order to capture as much value as possible from the planned clinical trial."

About Therapeutic Solutions International, Inc.
Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com, and our public forum is https://board.therapeuticsolutionsint.com/ 

1 Study confirms longer-term lung damage after COVID-19 (newswise.com)

ir@tsoimail.com

 

View original content:https://www.prnewswire.com/news-releases/therapeutic-solutions-international-discovers-and-files-patent-on-novel-cellular-therapy-combination-for-augmentation-of-lung-repair-in-covid-19-model-301382566.html

SOURCE Therapeutic Solutions International

FAQ

What key findings were reported by Therapeutic Solutions International regarding lung injury?

The company reported that the combination of T regulatory cells and JadiCells effectively suppresses lung damage in experimental models.

What is the significance of the GITR pathway discovered in the research by TSOI?

The GITR pathway is suggested to play a crucial role in enhancing the efficacy of the cellular therapy, potentially leading to improved patient outcomes.

When is Therapeutic Solutions International's FDA Phase III trial scheduled to begin?

The company is preparing to initiate the Phase III trial, indicating imminent steps in clinical testing.

How does the new therapy from TSOI address lung damage caused by COVID-19?

The therapy aims to reduce lung scarring, a common issue in COVID-19 patients, thus helping improve lung function.